These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28594276)

  • 1. Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.
    Rizzuto I; Ghazaly E; Peters GJ
    Pharmacogenomics; 2017 Jun; 18(9):911-925. PubMed ID: 28594276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
    Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
    Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
    Hodge LS; Taub ME; Tracy TS
    Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular pharmacology of gemcitabine.
    Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
    Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does saturable formation of gemcitabine triphosphate occur in patients?
    Tham LS; Wang LZ; Soo RA; Lee HS; Lee SC; Goh BC; Holford NH
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):55-64. PubMed ID: 18305939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
    Heinemann V; Xu YZ; Chubb S; Sen A; Hertel LW; Grindey GB; Plunkett W
    Cancer Res; 1992 Feb; 52(3):533-9. PubMed ID: 1732039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
    Grégoire V; Rosier JF; De Bast M; Bruniaux M; De Coster B; Octave-Prignot M; Scalliet P
    Radiother Oncol; 2002 Jun; 63(3):329-38. PubMed ID: 12142097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response.
    Blackstock AW; Lightfoot H; Case LD; Tepper JE; Mukherji SK; Mitchell BS; Swarts SG; Hess SM
    Clin Cancer Res; 2001 Oct; 7(10):3263-8. PubMed ID: 11595723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
    Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL
    Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
    van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
    Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.
    Veltkamp SA; Beijnen JH; Schellens JH
    Oncologist; 2008 Mar; 13(3):261-76. PubMed ID: 18378536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
    Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
    Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line.
    Hammond JR; Lee S; Ferguson PJ
    J Pharmacol Exp Ther; 1999 Mar; 288(3):1185-91. PubMed ID: 10027857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
    Grunewald R; Abbruzzese JL; Tarassoff P; Plunkett W
    Cancer Chemother Pharmacol; 1991; 27(4):258-62. PubMed ID: 1998982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
    Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters.
    Mackey JR; Yao SY; Smith KM; Karpinski E; Baldwin SA; Cass CE; Young JD
    J Natl Cancer Inst; 1999 Nov; 91(21):1876-81. PubMed ID: 10547395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
    Muggia F; Diaz I; Peters GJ
    Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.
    Bapiro TE; Richards FM; Goldgraben MA; Olive KP; Madhu B; Frese KK; Cook N; Jacobetz MA; Smith DM; Tuveson DA; Griffiths JR; Jodrell DI
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1243-53. PubMed ID: 21431415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine: a critical nucleoside for cancer therapy.
    Gesto DS; Cerqueira NM; Fernandes PA; Ramos MJ
    Curr Med Chem; 2012; 19(7):1076-87. PubMed ID: 22257063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical characteristics of gemcitabine.
    Plunkett W; Huang P; Gandhi V
    Anticancer Drugs; 1995 Dec; 6 Suppl 6():7-13. PubMed ID: 8718419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.